Latest Headlines
Age should not affect chemotherapy choice for stage IV lung cancer: guidelines
Early PET-CT predicts treatment response of head and neck cancer
Evidence scarce to support RF ablation of colorectal CA metastases in the liver
Casopitant helps curb chemotherapy emesis
Australian scientists plan to regrow breasts after cancer
NEWS PROVIDED BY 
VIEW ALL NEWSEGFR plus radiation raises risk of dermatologic toxicity
NEW YORK (Reuters Health) - Pooled data from studies involving numerous patients show that while addition of epidermal growth factor receptor (EGFR) inhibitors to radiotherapy has improved action against solid tumors, it has also increased radiation dermatitis.
"Whereas the pivotal study of cetuximab combined with radiotherapy against head and neck cancer did not show any greater skin toxicity," senior investigator Dr. Mario E. Lacouture told Reuters Health, "our meta-analysis of large patient groups suggests that there is a greater risk of severe skin and mucosal side effects when an EGFR inhibitor is administered concurrently with radiation."
"These findings," he added, "underscore the need for better prophylactic and management strategies for patients receiving these combined regimens."
Dr. Lacouture of Northwestern University, Chicago, and colleagues analyzed reports of radiation dermatitis, rash, and mucositis from 24 phase 1, 2, and 3 trials involving 933 patients. Randomized trials of radiotherapy and chemoradiation were used as controls.
According to their article in the March 15th issue of Cancer, the EGFR inhibitor combination regimen gave a risk ratio for radiation dermatitis of 2.38 compared with radiotherapy alone. The risk ratio for rash was 3.01, and for mucositis it was 1.76, suggesting an enhanced risk of dermatologic toxicities.
"With increasing use of EGFR inhibitors plus radiation," concluded Dr. Lacouture, "greater skin side effects are important not only because they affect quality of life, but they may also impact consistent administration of therapy, affecting cancer control and patient survival."
Copyright © 2009 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.
NEWS PROVIDED BY
TEXT SIZE 